Attached files

file filename
EX-99.1 - EX-99.1 - Coherus BioSciences, Inc.d87814dex991.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2015

 

 

COHERUS BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36721   27-3615821

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

201 Redwood Shores Parkway, Suite 200

Redwood City, CA 94065

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 649-3530

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 2.02 Results of Operations and Financial Conditions

On August 10, 2015, Coherus BioSciences, Inc. (the “Company”) issued a press release reporting its financial results for its second quarter ended June 30, 2015. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.

This information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On August 6, 2015, the Compensation Committee of the Board of Directors of the Company approved the following annual base salaries, effective as of July 1, 2015 for the named executive officers of the Company, as identified the Company’s final Prospectus related to its secondary public offering, which was filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on April 1, 2015:

 

Executive Name    Position    2014 Base Salary     

New Base Salary

Effective July 1,

2015

 
Dennis M. Lanfear    President & Chief Executive Officer    $ 450,000       $ 561,700   
Barbara K. Finck, M.D    Chief Medical Officer    $ 375,000       $ 407,500   
Alan C. Herman, Ph.D.    Chief Scientific Officer    $ 350,000       $ 412,000   
Peter K. Watler, Ph.D.    Chief Technology Officer    $ 335,000       $ 341,700   
Jean-Frédéric Viret, Ph.D.    Chief Financial Officer    $ 350,000       $ 373,000   

The Company will provide additional information regarding the compensation paid to the named executive officers for fiscal year 2015 in its definitive proxy statement for the 2016 Annual Meeting of Stockholders, which is expected to be filed with the Securities and Exchange Commission in the second quarter of 2016.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

  

Description

99.1    Press Release dated August 10, 2015


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:    August 10, 2015   COHERUS BIOSCIENCES, INC.
  By:  

/s/ Jean-Frédéric Viret

  Name:    Jean-Frédéric Viret
  Title:   Chief Financial Officer


EXHIBIT INDEX

 

Exhibit No.

  

Description

99.1    Press Release dated August 10, 2015